Tags: US | OSI | Pharma | Cancer | Drug

FDA Says OSI Drug Effective Against Lung Cancer

Monday, 14 Dec 2009 11:24 AM

Federal health regulators say OSI Pharmaceutical's Tarceva slows the progression of lung cancer when given to patients who have received chemotherapy.

OSI wants the Food and Drug Administration to approve Tarceva as a maintenance therapy, or a drug designed to stop cancer from spreading in patients who respond to chemotherapy. It is currently approved as a secondary treatment for patients who have not responded to chemotherapy.

A company study showed Tarceva lengthened patients lives about three months when taken immediately following chemotherapy.

The FDA on Wednesday will ask a panel of outside experts to compare Tarceva's performance with a similar drug marketed by Sanofi Aventis.

© Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

 
1Like our page
2Share
Companies
Federal health regulators say OSI Pharmaceutical's Tarceva slows the progression of lung cancer when given to patients who have received chemotherapy.OSI wants the Food and Drug Administration to approve Tarceva as a maintenance therapy, or a drug designed to stop cancer...
US,OSI,Pharma,Cancer,Drug
105
2009-24-14
Monday, 14 Dec 2009 11:24 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved